Director/PDMR Shareholding

RNS Number : 7796D

Epistem Holdings plc

29 March 2011

 

Company         Epistem Plc

TIDM                EHP.L (AIM)

Headline          Senior Executive Incentive Package

Released         29 March 2011 : 7.00AM

Number           

Epistem Plc

("Epistem" or "the Company")

Senior Executive Incentive Package

The Board of Epistem (AIM: EHP), the rapidly growing biotechnology company, recognises the importance of incentivising and rewarding the performance of its key executives and tasked the remuneration committee to review the long term incentive plan for its senior executives.

Following the recommendation of the remuneration committee, the Company has today made the following award to Matthew Walls, CEO:

• options over 260,000 ordinary shares of £0.015p each, representing 3% of the current issued share capital of the Company, exercisable at 372.5p per share, being the current market value of Epistem's shares. These options are subject to the Company achieving a compound annual growth in EBITDA of at least 15% for the three year period commencing 1 July 2010 to 30 June 2013.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer                            ++44 161 606 7258                         

John Rylands, Chief Financial Officer                                          

Peel Hunt LLP

Nominated Adviser: James Steel/Vijay Barathan               ++44 207 418 8900

De Facto Financial Ltd

Mike Wort/Anna Dunphy                                                 ++44 207 861 3838

Notes for editors

Epistem is a biotechnology and personalised medicine company commercialising its expertise in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics, biomarkers, diagnostics and provides contract research services to drug development companies. The Group's core expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation. The Group has specialist knowledge of the effects of radiation on adult epithelial stem cells and tissue and is developing novel therapies for treatment of mucositis and radiation sickness (acute radiation syndrome) alongside its proprietary preclinical models.

Epistem operates three distinct business divisions, Contract Research Services, Novel Therapies and Personalised Medicine (Biomarkers and Diagnostics).

 

END

 

 

RDSBRGDXSXDBGBI